Management options for stage i seminoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 7, 2010, Pages 1077-1085

  Aparicio, Jorge ^a   Daz, Roberto ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

chemotherapy; prognostic factor; radiation therapy; risk adapted therapy; seminoma; stage I; surveillance

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; FLUORODEOXYGLUCOSE F 18; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HISTOLOGY; HUMAN; MORBIDITY; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PARAAORTIC LYMPH NODE; PATIENT ATTITUDE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RETE TESTIS; RETROPERITONEAL CANCER; REVIEW; RISK ASSESSMENT; SECOND CANCER; SEMINOMA; SYNCYTIOTROPHOBLAST; TESTIS CANCER; TESTIS DISEASE; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; MALE; PATHOLOGY; RISK; TESTICULAR NEOPLASMS; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; MALE; MODELS, THEORETICAL; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RISK; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 77954866764     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.82     Document Type: Review

References (88)

1. Dearnaley DP, Huddart RA, Horwich A. Managing testicular cancer. BMJ 322, 1583-1588 (2001).
2. McGlynn KA, Devesa SS, Sigurdson AJ et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97, 63-70 (2003).
3. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N. Engl. J. Med. 337, 242-253 (1997).
4. Germa-Lluch JR, Garoa del Muro X, Maroto P et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur. Urol. 42, 553-563 (2002).
5. Aparicio J, Germa JR. Treatment of stage I testicular germ-cell tumors. Med. Oncol. 23, 305-315 (2006).
6. Feldman DR, Bosl GJ. Treatment of stage I seminoma: is it time to change your practice? J. Hematol. Oncol. 1, 22-24 (2008).
7. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. Stage I testicular seminoma: management and controversies. Crit. Rev. Oncol. Hematol. 71, 22-28 (2009).
8. Skilarenko J, Vesprini D, Warde P. Stage I seminoma: what should a practicing uro-oncologist do in 2009? Int. J. Urol. 16, 544-551 (2009).
9. Lawrentschuk N, Fleshner NE. Therapeutic options following orchiectomy for stage I seminoma. Oncology 23, 1-7 (2009).
10. Stephenson AJ. Current treatment options for clinical stage I seminoma. World J. Urol. 27, 427-432 (2009).
11. Jones RH, Vasey PA. Testicular cancer - management of early disease. Lancet Oncol. 4, 730-737 (2003).
12. Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat. Rev. 28, 237-253 (2002).
13. Chung P, Mayhew LA, Warde P et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin. Oncol. 22, 6-16 (2010).
14. Heidenreich A, Weissbach L, Holtl W et al. Organ sparing surgery for malignant germ cell tumor of the testis. J. Urol. 166, 2161-2165 (2001).
15. Chung PWM, Bayley AJD, Sweet J et al. Spermatocytic seminoma: a review. Eur. Urol. 45, 495-498 (2004).
16. Hilton S, Herr HW, Teitcher JB et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer. AJR Am. J. Roentgenol. 169, 521-525 (1997).
17. Spermon JR , de Greus-Oei LF, Kiemeney LAL et al. The role of FDG-PET in initial staging and restaging after chemotherapy for testicular germ cell tumours. Br. J. Urol. Int. 89, 549-556 (2002).
18. Fizazi K, Auperin A, Le Moulec S et al. Stage I seminoma: can positron emission tomography (FDG-PET) predict occult dissemination? A Phase II study. Presented at: AS CO Genitourinary Cancers Symposium. CA, USA 14-16 February, 2008 (Abstract 280).
19. Schultz HP, von der Maase A, Rorth M et al. Testicular seminoma in Denmark 1976-1980. Acta Radiol. Oncol. 23, 263-270 (1984).
20. Willan BD, McGowan DG. Seminoma of the testis: a 22-year experience with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 11, 1769-1775 (1985).
21. Thomas GM. Controversies in the management of testicular seminoma. Cancer 55, 2296-2302 (1985).
22. Hamilton C, Horwich A, Easton D et al. Radiotherapy for stage I seminoma testis: results and treatment complications. Radiother. Oncol. 6, 115-120 (1986).
23. Zagars GK, Babaian RJ. Stage I testicular seminoma: rationale for postorchidectomy radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 13, 155-162 (1987).
24. Fossa SD, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int. J. Radiat. Oncol. Biol. Phys. 16, 383-389 (1989).
25. Sommer K, Brockmann WP, Hubener KH. Treatment results and acute and late toxicity of radiation therapy for testicular seminoma. Cancer 66, 259-263 (1990).
26. Bayens YC, Helle PA, Van PW et al. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. Radiother. Oncol. 25, 97-102 (1992).
27. Giacchetti S, Raoul Y, Wibault P et al. Treatment of stage I testis seminoma by radiotherapy: long-term results - a 30-year experience. Int. J. Radiat. Oncol. Biol. Phys. 27, 3-9 (1993).
28. Dosmann MA, Zagars GK. Post- orchiectomy radiotherapy for stages I and II testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys. 26, 381-390 (1993).
29. Warde P, Gospodarowicz MK, Panzarella T et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J. Clin. Oncol. 13, 2255-2262 (1995).
30. Tana S, Cerrotta A, Gardani G et al. Postsurgical policy in stage I testicular seminoma: cost and benefit of prophylactic irradiation in a long term experience. Tumori 83, 918-921 (1997).
31. Coleman JM, Coleman RE, Turner AR et al. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. J. Clin. Oncol. 10, 237-241 (1998).
32. Zagars GK. Management of stage I seminoma: radiotherapy. In: Testicular Cancer: Investigation and Management (2ndEdition). Horwich A (Ed.). Chapman and Hall, London, UK 99-121 (1996).
33. Huddart RA, Norman A, Shaidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513-1523 (2003).
34. Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of irradiation. Int. J. Radiat. Oncol. Biol. Phys. 24, 913-919 (1992).
35. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89, 1429-1439 (1997).
36. Zagars GK, Ballo MT, Lee AK, Storm SS. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22, 640-647 (2004).
37. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1429-1439 (2005).
38. Vudarla N, Jawed I, Kaya H et al. Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: a Surveillance, Epidemiology, and End Results (SEER) analysis. J. Clin. Oncol. 25(SUPPL.), (2007) (Abstract 5020).
39. Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomised trial. J. Clin. Oncol. 17, 1146-1154 (1999).
40. Jones WG, Fossa SD, Mead GM et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23, 1200-1208. (2005).
41. Logue JP, Harris MA, Livsey JE et al. Short course para-aortic radiation for stage I seminoma of the testis. Int. J. Radiat. Oncol. Biol. Phys. 57, 1304-1309 (2003).
42. Classen J, Schmidberger H, Meisner C et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br. J. Cancer 90, 2305-2311 (2004).
43. Hoffman KE, Chen M-H, Punglia RS et al. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I seminoma. J. Clin. Oncol. 26, 3937-3942 (2008).
44. Germa-Lluch JR, Climent MA, Villavicencio H et al. Treatment of stage I testicular tumours. Br. J. Urol. 71, 473-477 (1993).
45. Duchesne GM, Horwich A, Dearnaley DP et al. Orchiectomy alone for stage I seminoma of the testis. Cancer 65, 1115-1118 (1990).
46. Horwich A, Alsanjari N, A'Hern R et al. Surveillance following orchidectomy for stage I testicular seminoma. Br. J. Cancer 65, 775-778 (1992).
47. von der Maase H, Specht L, Jacobsen GK et al. Surveillance following orchiectomy for stage I seminoma of the testis. Eur. J. Cancer 14, 1931-1934 (1993).
48. Warde P, Gospodarowicz M, Panzarella T et al. Surveillance is an appropriate management strategy in patients with stage I testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys. 54, 61-65 (2002).
49. Tolan S, Vesprini D, Jewett MAS et al. No role for routine chest radiography in stage I seminoma surveillance. Eur. Urol. 57, 474-479 (2010).
50. Ramakrishnan S, Champion AE, Dorreen MS et al. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine radiotherapy? J. Clin. Oncol. 4, 284-286 (1992).
51. Allhoff EP, Liedke S, de Riese W et al. Stage I seminoma of the testis. Adjuvant radiotherapy or surveillance? Br. J. Urol. 68, 190-194 (1991).
52. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 111, 76-83 (2003).
53. Yu HY, Madison RA, Setodji CM, Saigal CS. Quality of surveillance for stage I testis cancer in the community. J. Clin. Oncol. 27, 4327-4332 (2009).
54. Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: a 15-year review. Urol. Oncol. 24, 180-183 (2006).
55. Bosl GJ, Vogelzang NJ, Goldman A et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 2, 970-973 (1981).
56. Moynihan C. Testicular cancer: the psychosocial problems of patients and their relatives. Cancer Surv. 6, 477-510 (1987).
57. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit. Rev. Oncol. Hematol 64, 182-197 (2007).
58. Martin JM, Panzarella T, Zwahlen DR et al. Evidence-based guidelines for following stage I seminoma. Cancer 109, 2248-2256 (2007).
59. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J. Clin. Oncol. 14, 2933-2939 (1996).
60. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N. Engl. J. Med. 357, 2277-2284 (2007).
61. Oliver RT, Edmonds PM, Ong YJ et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 29, 3-8 (1994).
62. Dieckmann KP, Bruggeboes B, Pichlmeier U et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55, 102-106 (2000).
63. Reiter WJ, Brodowicz T, Alavi S et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J. Clin. Oncol. 19, 101-104 (2001).
64. Steiner H, Holtl L, Wirtenberger W et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 60, 324-328 (2002).
65. Krege S, Kalund G, Otto T et al. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur. Urol. 31, 405-407 (1997).
66. Oliver R, Boubilkova L, Ong J. Fifteen- year follow-up of the Anglian Germ Cell Cancer group adjuvant studies of carboplatin as an alternative to radiation or surveillance for stage I seminoma. Proc. ASCO 19, (2001) (Abstract 780).
67. Argirovic D. Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy: the experience in the management of 300 consecutive patients. J. BUON 10, 195-200 (2005).
68. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet 366, 293-300 (2005).
69. Kopf-Maier P. Effects of carboplatin on the testis. A histological study. Cancer Chemother. Pharmacol. 29, 227-235 (1992).
70. Reiter WJ, Kratzik C, Brodowicz T et al. Sperm analysis and serum follicle- stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Urology 52, 117-119 (1998).
71. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann. Oncol. 19, 443-447 (2008).
72. Oliver RT, Mead GM, Fogarty PJ et al. Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/ EORTC randomized trial. J. Clin. Oncol. 26(SUPPL.), 1 (2008) (Abstract).
73. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20, 4448-4452 (2002).
74. Aparicio J, Garcia-Puche J, Lomas M et al. Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: a multivariate analysis on 588 cases (abstr). J. Clin. Oncol. 24(SUPPL.), (2006) (Abstract 229S).
75. Mead GM, Fossa SD, Oliver RT et al. Relapse patterns in 2,466 stage 1 seminoma patients entered into Medical Research Council randomized trials (abstr). J. Clin. Oncol. 26, (2008) (Abstract 255S).
76. Aparicio J, Garoa del Muro X, Maroto P et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann. Oncol. 14, 867-872 (2003).
77. Aparicio J Germa JR, Garoa del Muro X et al. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Group study. J. Clin. Oncol. 23, 8717-8723 (2005).
78. Warde P, Gospodarowicz M. Adjuvant carboplatin in stage I seminoma. Lancet 366, 267-268 (2005).
79. Loehrer PJ, Bosl GJ. Carboplatin for stage I seminoma and the sword of Damocles. J. Clin. Oncol. 23, 8566-8569 (2005).
80. Oliver T, Mead G, Mason M et al. The sword of Damocles and the treatment of stage I seminoma. J. Clin. Oncol. 24, 2599-2600 (2006).
81. Aparicio J, Germa JR. Myths and facts on adjuvant carboplatin for stage I seminoma. J. Clin. Oncol. 24(21), E40 (2006).
82. Gilligan T, Oh WK, Kantoff PW. Carboplatin for stage I seminoma. J. Clin. Oncol. 24, 2971-2972 (2006).
83. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur. Urol. 53, 478-496 (2008).
84. Improving Outcomes in Urological Cancers. National Institute for Health and Clinical Excellence, London, UK (2002).
85. Wood L, Wilke D, Rutledge R et al. Guidelines for the Management of Adult Testicular Cancer. Genitourinary Cancer Site Team, Cancer Care Nova Scotia, Canada (2004; revised 2005).
86. Motzer RJ, Bahson RR, Boston B et al. Testicular cancer. Clinical practice guidelines. J. Natl Compr. Cancer Netw. 3, 52-76 (2005).
87. Albers P, Albrecht W, Algaba F et al. European Association of Urology guidelines on testicular cancer (2010) www.uroweb.org
88. National Comprehensive Cancer Network clinical practice guidelines in oncology, testicular cancer VI (2009) www.nccn.org